Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as First Line Treatment for Metastatic or Locally Advanced Urothelial Carcinoma
Clinical trial NCT06657157 · RECRUITING
Trial details
- NCT number
- NCT06657157
- Sponsor
- Comprehensive Cancer Center Munich (CCCM)
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2025-01-22
- Primary completion
- 2026-12-01
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.